Skip to content
Save at BioLongevity Labs with code EVERYDAY•Save at S1 Research with code everydaypeptide•Save at Alpha Peptides with code EVERYDAY•Save at Ion Peptide with code EVERYDAY•Save at Solution Peptides with code EVERYDAY15•Save at Atomik Labz with code EVERYDAY25•Save at Next Gen Peps with code EVERYDAY•
Save at BioLongevity Labs with code EVERYDAY•Save at S1 Research with code everydaypeptide•Save at Alpha Peptides with code EVERYDAY•Save at Ion Peptide with code EVERYDAY•Save at Solution Peptides with code EVERYDAY15•Save at Atomik Labz with code EVERYDAY25•Save at Next Gen Peps with code EVERYDAY•
EVERYDAYPEPTIDES
  • Peptides
  • Vendors
  1. Home
  2. Peptides
  3. Thymagen

Other

Thymagen

Thymagen is a research-use product carried by vendors we track. For research use only; an editorial review is pending.

PreclinicalResearch use only

About Thymagen

Thymagen is offered by one or more vendors we track. We have not yet written a detailed editorial summary for this compound. The offerings below reflect what vendors currently carry. For research use only — verify dosing, handling, and safety against primary sources.

Category
Other
Typical dose
--
Vial sizes
--
Half-life
--
Administration
--
Goals

Where to buy

Vendor offerings

Some links on this page are affiliate links. We may earn a commission when you purchase through them, at no extra cost to you.

  • Thymagen (Thymogen) (20mg) from BioLongevity Labs
    BioLongevity LabsTested

    Thymagen (Thymogen) (20mg)

    $79.97

    $4.00/mg · 20mg

    EVERYDAY
    Shop on BioLongevity Labs

Evidence level

Preclinical only

A short synthetic peptide (Glu-Trp) marketed in Russia as an immune-modulating thymic bioregulator. Part of the Khavinson short-peptide bioregulator family. Published evidence is almost entirely from the originating research network; independent Western replication is lacking.

Mechanism

Mechanism not yet documented.

Researched benefits

  • Claimed immune modulation

    Russian-language reports describe restoration of T-cell parameters in immunosuppressed patients, post-infectious cohorts, and elderly populations. Sample sizes are typically small and trial designs do not meet Western blinding/randomization standards.

  • Thymic bioregulator framing

    Conceptually positioned as a synthetic dipeptide analog of natural thymic factors (alongside Thymalin, a thymus-derived peptide fraction). The Khavinson framework proposes tissue-specific transcriptional effects, though the molecular mechanism is not confirmed in independent biochemistry.

  • Reported clinical use in Russia

    Available as a registered drug in Russia (Timogen, Thymogen) since the 1980s for immune support in respiratory infections and post-surgical recovery. Regulatory acceptance there reflects the Russian pharmacological tradition rather than Western RCT-based standards.

Risks & cautions

  • moderate

    Limited safety data outside Russian sources

    Decades of Russian clinical use suggest the peptide is not acutely toxic, but formal safety dossiers meeting Western regulatory standards do not exist.

  • moderate

    Efficacy uncertainty

    Effectively all positive efficacy data comes from the originating Khavinson research network. No independent Western randomized blinded trials exist.

  • moderate

    Theoretical immune dysregulation

    Any immunomodulator carries theoretical risk in autoimmune disease or active malignancy. No specific signal has been reported but the data to detect such signals is limited.

  • low

    Injection-site reactions

    Standard subcutaneous risks: local erythema, mild bruising. No unique signal.

Dosing

Commonly reported: 100 mcg subcutaneously or intranasally daily for 7–10 days, often repeated in 2–3 month cycles. Protocols are based on Russian clinical practice rather than dose-finding trials.

Conservative
100 mcg daily × 5 days
Standard
100 mcg daily × 7–10 days
Aggressive
100 mcg daily × 10 days, repeated

Vial sizes

--

Half-life

--

Route

--

Russian registered formulations (Timogen) include both injectable and intranasal preparations. Half-life of a dipeptide is very short; effects are presumed to derive from downstream signaling rather than sustained plasma exposure. Cycles rather than continuous dosing are standard.

Contraindications

  • Active autoimmune disease (theoretical caution given immune-modulating framing)
  • Active malignancy without supervision
  • Pregnancy or breastfeeding — no Western safety data
  • Known peptide hypersensitivity

In depth

Background

Thymagen (also spelled Timogen, Thymogen) is a dipeptide — glutamyl-tryptophan (Glu-Trp) — developed in the Soviet/Russian thymic peptide research program. Native Thymalin is a peptide mixture extracted from calf thymus; Thymagen is a defined synthetic dipeptide proposed as the minimal active sequence retaining thymic bioregulator activity.

The compound has been registered as a pharmaceutical product in Russia for several decades, used in clinical practice for immune support in respiratory infections, post-surgical recovery, and various immunodeficient states. It sits within the broader Khavinson short-peptide bioregulator framework alongside Cortexin, Epitalon, Cortagen, Pinealon, and others.

Important framing caveat: as with the rest of the Khavinson family, essentially all positive efficacy data originates from a single research network. The peptides are well-known in Russian and adjacent clinical traditions but have not been independently validated by Western pharmacological research. Russian regulatory acceptance reflects a different evidentiary tradition, not a vacuum of evidence — but the data quality gap matters when interpreting claims.

Mechanism in depth

Proposed mechanism within the Khavinson framework: short peptides can penetrate cells and even nuclei, where they interact with chromatin and modulate transcription of tissue-specific gene programs. For Thymagen the proposed target tissue is thymic and peripheral lymphocyte populations.

More biochemically conservative interpretations of dipeptide signaling would invoke:

  1. Cell-surface receptor effects — Glu-Trp could interact with surface receptors on lymphocytes or thymic epithelial cells, though no specific receptor has been characterized.
  2. Peptide-amino acid signaling — dipeptides break down rapidly; observed effects could reflect amino acid signaling (Trp particularly, which has signaling roles via kynurenine and tryptophan-restriction pathways).
  3. Adjuvant-like effects — short peptides can modulate antigen presentation indirectly.

The actual molecular mechanism remains uncharacterized in independent pharmacology.

Human evidence

Russian-language clinical reports describe:

  • Improved T-cell subset numbers (CD4, CD8) in immunosuppressed patients.
  • Faster recovery from upper respiratory infections.
  • Reduced post-surgical infection rates.

Trial designs are typically small (n<100), often open-label or single-blind, and use surrogate immunologic endpoints. Western randomized blinded placebo-controlled trials are essentially absent from the indexed literature.

Animal evidence

Within the Khavinson program, rodent and rabbit studies report normalization of T-cell parameters after experimental immunosuppression. Outside that program, dedicated Thymagen animal pharmacology is sparse.

Stack synergy

In Russian clinical practice Thymagen is sometimes combined with other Khavinson bioregulators (Cortexin for cerebral protection, Epitalon for pineal/longevity contexts) in multi-peptide protocols. There is no rigorous data on additive effects.

In Western research-peptide practice, Thymagen sometimes appears in immune-support or recovery stacks alongside BPC-157, TB-500, or thymosin alpha-1 (a much better-studied thymic peptide). Combining with thymosin alpha-1 is mechanistically overlapping; the additive effect is unstudied.

Caution combining with other immunomodulators (TA-1, LL-37, KPV) without clear rationale — additive effects on immune signaling are unpredictable.

Open questions

  • Does Thymagen produce a reproducible immunologic effect in independent (non-Khavinson-network) laboratories?
  • What is the actual mechanism at the molecular level? Three decades of clinical use have not produced a clear receptor or biochemical target outside the originating framework.
  • How does Thymagen compare to thymosin alpha-1 — a 28-amino-acid thymic peptide with substantially better Western evidence for immune modulation in viral infections and as a vaccine adjuvant?
  • What is the long-term safety profile in any rigorous registry? Russian clinical use is decades-long, but formal pharmacovigilance data to Western standards is sparse.

References

  1. 1.Khavinson V.K. — Peptides and ageing (Neuro Endocrinology Letters, 2002)
  2. 2.Morozov V.G., Khavinson V.K. — Natural and synthetic thymic peptides as therapeutics for immune dysfunction (International Journal of Immunopharmacology, 1997)
  3. 3.Saint Petersburg Institute of Bioregulation and Gerontology — Khavinson peptide bioregulator series

Everyday Peptides

Independent peptide guides and vendor comparison. Research-grade information for adult researchers.

Browse

  • All peptides
  • All vendors

About

  • About us
  • Contact

Legal

  • Affiliate disclosure
  • Privacy

(c) 2026 Everyday Peptides. Some links on this site are affiliate links. We may earn a commission when you purchase through them, at no extra cost to you.

All content is for educational purposes only and is not medical advice. Peptides discussed are for research use only.